Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689229 | 1.00 | KMT2A (0.72) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL26634309 | 0.87 | KMT2A (0.78) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL31689244 | 0.87 | KMT2A (0.78) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL5798271 | 0.86 | KMT2A (0.53) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL31689249 | 0.85 | KMT2A (0.79) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL26634201 | 0.85 | KMT2A (0.79) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL26634085 | 0.83 | KMT2A (1.00) | KMT2AMEN1MAPK1BRD4MAPT | |
| SCHEMBL26634411 | 0.83 | MAPK1 (0.68) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL31689333 | 0.83 | MAPK1 (0.68) | KMT2AMEN1MAPK1HDAC2HDAC8 | |
| SCHEMBL26634339 | 0.83 | MAPK1 (0.68) | KMT2AMEN1MAPK1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4518968-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | Cytokinetics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023215367-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNI3, TNNC1 | KMT2A 3619/4885MEN1 3950/4885MAPK1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.